Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial

Int J Obes (Lond). 2006 Dec;30(12):1729-36. doi: 10.1038/sj.ijo.0803344. Epub 2006 Apr 18.


Background: Oxyntomodulin has recently been found to decrease body-weight in obese humans and may be a potential anti-obesity therapy.

Objective: To determine whether oxyntomodulin alters energy expenditure, in addition to reducing energy intake, in 'free-living' overweight and obese volunteers.

Design: Randomized double-blind controlled cross-over trial.

Setting: Community and hospital-based.

Participants: Fifteen healthy overweight and obese men and women (age: 23-49 years, BMI: 25.1-39.0 kg/m(2)). All volunteers completed the study protocol.

Interventions: Four-day subcutaneous self-administration of pre-prandial oxyntomodulin, three times daily. Participants were advised to maintain their normal dietary and exercise regimen.

Measurements: (1) Energy expenditure, measured by indirect calorimetry and combined heart rate and movement monitoring; (2) energy intake, measured during a study meal.

Results: Oxyntomodulin administration reduced energy intake at the study meal by 128+/-29 kcal (P=0.0006) or 17.3+/-5.5% (P=0.0071), with no change in meal palatability. Oxyntomodulin did not alter resting energy expenditure; but increased activity-related energy expenditure by 143+/-109 kcal/day or 26.2+/-9.9% (P=0.0221); total energy expenditure by 9.4+/-4.8% (P=0.0454) and physical activity level by 9.5+/-4.6% (P=0.0495). A reduction in body weight of 0.5+/-0.2% was observed during the oxyntomodulin administration period (P=0.0232).

Conclusion: Oxyntomodulin increases energy expenditure while reducing energy intake resulting in negative energy balance. This data supports the role of oxyntomodulin as a potential anti-obesity therapy.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anti-Obesity Agents / adverse effects
  • Anti-Obesity Agents / blood
  • Anti-Obesity Agents / pharmacology*
  • Anti-Obesity Agents / therapeutic use
  • Blood Pressure / drug effects
  • Body Mass Index
  • Cross-Over Studies
  • Double-Blind Method
  • Energy Intake / drug effects*
  • Energy Metabolism / drug effects*
  • Female
  • Heart Rate / drug effects
  • Humans
  • Injections, Subcutaneous
  • Insulin / blood
  • Male
  • Middle Aged
  • Obesity / blood
  • Obesity / drug therapy*
  • Obesity / physiopathology
  • Overweight / drug effects
  • Oxyntomodulin / adverse effects
  • Oxyntomodulin / blood
  • Oxyntomodulin / pharmacology*
  • Oxyntomodulin / therapeutic use
  • Self Administration


  • Anti-Obesity Agents
  • Insulin
  • Oxyntomodulin